NCT02532231View on ClinicalTrials.gov

Nivolumab in AML in Remission at High Risk for Relapse

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

August 8, 2023

Study Completion Date

August 8, 2023

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionBlasts Under 10 Percent of Bone Marrow Nucleated CellsTherapy-Related Myeloid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02532231 - Nivolumab in AML in Remission at High Risk for Relapse | Biotech Hunter | Biotech Hunter